NATURE . COM {}

Analyzed Page
Matching Content Categories
CMS
Monthly Traffic Estimate
How Does Nature.com Make Money
How Much Does Nature.com Make
Keywords
Topics
Questions
Schema
Social Networks
External Links
Analytics And Tracking
Libraries
Hosting Providers
CDN Services

We are analyzing https://www.nature.com/articles/nrc1821.

Title:
Validating matrix metalloproteinases as drug targets and anti-targets for cancer therapy | Nature Reviews Cancer
Description:
Clinical trial results with matrix metalloproteinase (MMP) inhibitors have been poor. So, which MMPs are validated drug targets with a crucial role in disease pathogenesis and which MMPs are actually proteins that have unacceptable deleterious effects when inhibited (anti-targets)? The matrix metalloproteinases (MMPs) mediate homeostasis of the extracellular environment. They have multiple signalling activities that are commonly altered during tumorigenesis and that might serve as intervention points for anticancer drugs. However, there are many criteria to consider in validating MMPs as drug targets and for the development of MMP inhibitors. The inhibition of some MMPs could have pro-tumorigenic effects (making them anti-targets), counterbalancing the benefits of target inhibition. These effects might partially account for the failure of MMP inhibitors in clinical trials. What are the major challenges in MMP target validation and MMP-inhibitor-drug development?
Website Age:
30 years and 10 months (reg. 1994-08-11).

Matching Content Categories {📚}

Education
Health & Fitness
Science

Content Management System {📝}

What CMS is nature.com built with?

Custom-built

No common CMS systems were detected on Nature.com, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of nature.com audience?

🌆 Monumental Traffic: 20M - 50M visitors per month

Based on our best estimate, this website will receive around 42,797,153 visitors per month in the current month.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Nature.com Make Money? {💸}

Display Ads {🎯}

The website utilizes display ads within its content to generate revenue. Check the next section for further revenue estimates.

Ads are managed by yourbow.com. Particular relationships are as follows:

Direct Advertisers (10)

google.com, pmc.com, doceree.com, yourbow.com, audienciad.com, onlinemediasolutions.com, advibe.media, aps.amazon.com, getmediamx.com, onomagic.com

Reseller Advertisers (38)

conversantmedia.com, rubiconproject.com, pubmatic.com, appnexus.com, openx.com, smartadserver.com, lijit.com, sharethrough.com, video.unrulymedia.com, google.com, yahoo.com, triplelift.com, onetag.com, sonobi.com, contextweb.com, 33across.com, indexexchange.com, media.net, themediagrid.com, adform.com, richaudience.com, sovrn.com, improvedigital.com, freewheel.tv, smaato.com, yieldmo.com, amxrtb.com, adyoulike.com, adpone.com, criteo.com, smilewanted.com, 152media.info, e-planning.net, smartyads.com, loopme.com, opera.com, mediafuse.com, betweendigital.com

How Much Does Nature.com Make? {💰}

Display Ads {🎯}

$539,300 per month
Our calculations suggest that Nature.com earns between $359,538 and $988,730 monthly online from display advertisements.

Keywords {🔍}

google, scholar, pubmed, cas, cancer, nature, matrix, metalloproteinase, breast, cell, inhibitors, biol, central, res, metalloproteinases, mmp, rev, human, chem, expression, access, cells, mice, article, drug, metastasis, research, therapy, tumor, med, british, columbia, content, target, collagen, matrisian, cookies, development, inhibition, science, protease, progression, privacy, targets, christopher, mmps, clinical, validation, open, discovery,

Topics {✒️}

permissions reprints nature portfolio privacy policy advertising mcp-1-tnfα cross-regulatory pathway cancer cell–adipocyte interaction/crosstalk discovery tools isotope-coded affinity tags author information authors double-blind placebo-controlled antisense rna-induced reduction blood research mmp-inhibitor-drug development biomedical research modify n-timp2 specificity isotope dilution-mass spectrometry author correspondence monocyte chemoattractant protein-3 nature cell biol national cancer institute social media ebsco media breast cancer development blood–brain barrier disruption cxcl12–cxcr4 chemotactic pathway leukolysin/mt6-mmp/mmp-25 gelatinase a-deficient mice personal data reciprocal tumor–microenvironment interactions mechanism-based gelatinase inhibitor springerlink instant access data protection permissions nature rev mass spectrometry-based proteomics nature neurosci structure-based drug design nature genet nature biotechnol nature med growth factor res canadian cancer association diet-induced obesity distinct collagen binding metalloproteinase substrate specificity metastatic potential correlates ben-baruch nature 284 nature 436 nature 390

Questions {❓}

What are the major challenges in MMP target validation and MMP-inhibitor-drug development?

Schema {🗺️}

WebPage:
      mainEntity:
         headline:Validating matrix metalloproteinases as drug targets and anti-targets for cancer therapy
         description:Clinical trial results with matrix metalloproteinase (MMP) inhibitors have been poor. So, which MMPs are validated drug targets with a crucial role in disease pathogenesis and which MMPs are actually proteins that have unacceptable deleterious effects when inhibited (anti-targets)? The matrix metalloproteinases (MMPs) mediate homeostasis of the extracellular environment. They have multiple signalling activities that are commonly altered during tumorigenesis and that might serve as intervention points for anticancer drugs. However, there are many criteria to consider in validating MMPs as drug targets and for the development of MMP inhibitors. The inhibition of some MMPs could have pro-tumorigenic effects (making them anti-targets), counterbalancing the benefits of target inhibition. These effects might partially account for the failure of MMP inhibitors in clinical trials. What are the major challenges in MMP target validation and MMP-inhibitor-drug development?
         datePublished:
         dateModified:
         pageStart:227
         pageEnd:239
         sameAs:https://doi.org/10.1038/nrc1821
         keywords:
            Biomedicine
            general
            Cancer Research
         image:
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1038%2Fnrc1821/MediaObjects/41568_2006_Article_BFnrc1821_Fig1_HTML.jpg
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1038%2Fnrc1821/MediaObjects/41568_2006_Article_BFnrc1821_Fig2_HTML.jpg
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1038%2Fnrc1821/MediaObjects/41568_2006_Article_BFnrc1821_Figa_HTML.jpg
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1038%2Fnrc1821/MediaObjects/41568_2006_Article_BFnrc1821_Figb_HTML.jpg
         isPartOf:
            name:Nature Reviews Cancer
            issn:
               1474-1768
               1474-175X
            volumeNumber:6
            type:
               Periodical
               PublicationVolume
         publisher:
            name:Nature Publishing Group UK
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:Christopher M. Overall
               affiliation:
                     name:University of British Columbia
                     address:
                        name:the University of British Columbia Centre for Blood Research, CBCRA Program in Breast Cancer Metastasis Departments of Oral Biological & Medical Sciences and Biochemistry & Molecular Biology, University of British Columbia, Vancouver, Canada
                        type:PostalAddress
                     type:Organization
                     name:the University of British Columbia Centre for Blood Research, 4.401 Life Sciences Institute
                     address:
                        name:the University of British Columbia Centre for Blood Research, 4.401 Life Sciences Institute, Vancouver, Canada
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
               name:Oded Kleifeld
               affiliation:
                     name:University of British Columbia
                     address:
                        name:the University of British Columbia Centre for Blood Research, CBCRA Program in Breast Cancer Metastasis, Departments of Oral Biological & Medical Sciences, and Biochemistry & Molecular Biology, University of British Columbia, Vancouver, Canada
                        type:PostalAddress
                     type:Organization
               type:Person
         isAccessibleForFree:
         hasPart:
            isAccessibleForFree:
            cssSelector:.main-content
            type:WebPageElement
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:Validating matrix metalloproteinases as drug targets and anti-targets for cancer therapy
      description:Clinical trial results with matrix metalloproteinase (MMP) inhibitors have been poor. So, which MMPs are validated drug targets with a crucial role in disease pathogenesis and which MMPs are actually proteins that have unacceptable deleterious effects when inhibited (anti-targets)? The matrix metalloproteinases (MMPs) mediate homeostasis of the extracellular environment. They have multiple signalling activities that are commonly altered during tumorigenesis and that might serve as intervention points for anticancer drugs. However, there are many criteria to consider in validating MMPs as drug targets and for the development of MMP inhibitors. The inhibition of some MMPs could have pro-tumorigenic effects (making them anti-targets), counterbalancing the benefits of target inhibition. These effects might partially account for the failure of MMP inhibitors in clinical trials. What are the major challenges in MMP target validation and MMP-inhibitor-drug development?
      datePublished:
      dateModified:
      pageStart:227
      pageEnd:239
      sameAs:https://doi.org/10.1038/nrc1821
      keywords:
         Biomedicine
         general
         Cancer Research
      image:
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1038%2Fnrc1821/MediaObjects/41568_2006_Article_BFnrc1821_Fig1_HTML.jpg
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1038%2Fnrc1821/MediaObjects/41568_2006_Article_BFnrc1821_Fig2_HTML.jpg
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1038%2Fnrc1821/MediaObjects/41568_2006_Article_BFnrc1821_Figa_HTML.jpg
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1038%2Fnrc1821/MediaObjects/41568_2006_Article_BFnrc1821_Figb_HTML.jpg
      isPartOf:
         name:Nature Reviews Cancer
         issn:
            1474-1768
            1474-175X
         volumeNumber:6
         type:
            Periodical
            PublicationVolume
      publisher:
         name:Nature Publishing Group UK
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:Christopher M. Overall
            affiliation:
                  name:University of British Columbia
                  address:
                     name:the University of British Columbia Centre for Blood Research, CBCRA Program in Breast Cancer Metastasis Departments of Oral Biological & Medical Sciences and Biochemistry & Molecular Biology, University of British Columbia, Vancouver, Canada
                     type:PostalAddress
                  type:Organization
                  name:the University of British Columbia Centre for Blood Research, 4.401 Life Sciences Institute
                  address:
                     name:the University of British Columbia Centre for Blood Research, 4.401 Life Sciences Institute, Vancouver, Canada
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
            name:Oded Kleifeld
            affiliation:
                  name:University of British Columbia
                  address:
                     name:the University of British Columbia Centre for Blood Research, CBCRA Program in Breast Cancer Metastasis, Departments of Oral Biological & Medical Sciences, and Biochemistry & Molecular Biology, University of British Columbia, Vancouver, Canada
                     type:PostalAddress
                  type:Organization
            type:Person
      isAccessibleForFree:
      hasPart:
         isAccessibleForFree:
         cssSelector:.main-content
         type:WebPageElement
["Periodical","PublicationVolume"]:
      name:Nature Reviews Cancer
      issn:
         1474-1768
         1474-175X
      volumeNumber:6
Organization:
      name:Nature Publishing Group UK
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:University of British Columbia
      address:
         name:the University of British Columbia Centre for Blood Research, CBCRA Program in Breast Cancer Metastasis Departments of Oral Biological & Medical Sciences and Biochemistry & Molecular Biology, University of British Columbia, Vancouver, Canada
         type:PostalAddress
      name:the University of British Columbia Centre for Blood Research, 4.401 Life Sciences Institute
      address:
         name:the University of British Columbia Centre for Blood Research, 4.401 Life Sciences Institute, Vancouver, Canada
         type:PostalAddress
      name:University of British Columbia
      address:
         name:the University of British Columbia Centre for Blood Research, CBCRA Program in Breast Cancer Metastasis, Departments of Oral Biological & Medical Sciences, and Biochemistry & Molecular Biology, University of British Columbia, Vancouver, Canada
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:Christopher M. Overall
      affiliation:
            name:University of British Columbia
            address:
               name:the University of British Columbia Centre for Blood Research, CBCRA Program in Breast Cancer Metastasis Departments of Oral Biological & Medical Sciences and Biochemistry & Molecular Biology, University of British Columbia, Vancouver, Canada
               type:PostalAddress
            type:Organization
            name:the University of British Columbia Centre for Blood Research, 4.401 Life Sciences Institute
            address:
               name:the University of British Columbia Centre for Blood Research, 4.401 Life Sciences Institute, Vancouver, Canada
               type:PostalAddress
            type:Organization
      email:[email protected]
      name:Oded Kleifeld
      affiliation:
            name:University of British Columbia
            address:
               name:the University of British Columbia Centre for Blood Research, CBCRA Program in Breast Cancer Metastasis, Departments of Oral Biological & Medical Sciences, and Biochemistry & Molecular Biology, University of British Columbia, Vancouver, Canada
               type:PostalAddress
            type:Organization
PostalAddress:
      name:the University of British Columbia Centre for Blood Research, CBCRA Program in Breast Cancer Metastasis Departments of Oral Biological & Medical Sciences and Biochemistry & Molecular Biology, University of British Columbia, Vancouver, Canada
      name:the University of British Columbia Centre for Blood Research, 4.401 Life Sciences Institute, Vancouver, Canada
      name:the University of British Columbia Centre for Blood Research, CBCRA Program in Breast Cancer Metastasis, Departments of Oral Biological & Medical Sciences, and Biochemistry & Molecular Biology, University of British Columbia, Vancouver, Canada
WebPageElement:
      isAccessibleForFree:
      cssSelector:.main-content

Social Networks {👍}(2)

External Links {🔗}(235)

Analytics and Tracking {📊}

Google Tag Manager

Libraries {📚}

Foundation
Isotope
Prism.js
Zoom.js

Emails and Hosting {✉️}

Mail Servers:

mxa-002c5801.gslb.pphosted.com
mxb-002c5801.gslb.pphosted.com

Name Servers:

pdns1.ultradns.net
pdns2.ultradns.net
pdns3.ultradns.org
pdns4.ultradns.org
pdns5.ultradns.info
pdns6.ultradns.co.uk

CDN Services {📦}

Crossref

4.64s.